2-蒽羧酸,7-氟-9,10-二氢-9,10-二羰基- | 1493-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 中文名称: 2-蒽羧酸,7-氟-9,10-二氢-9,10-二羰基-
• 英文名称: 7-fluoroanthraquinone-2-carboxylic acid
• 英文别名: 9,10-dihydro-9,10-dioxo-7-fluoroanthracene-2-carboxylic acid；7-Fluoro-9,10-dihydro-9,10-dioxo-2-anthroic acid；7-Fluor-anthrachinon-carbonsaeure-(2)；7-Fluor-anthrachinon-2-carbonsaeure；7-Fluoro-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid；7-fluoro-9,10-dioxoanthracene-2-carboxylic acid
• CAS: 1493-72-7
• 化学式: C₁₅H₇FO₄
• 分子量: 270.217
• InChiKey: IZTZPELUUGLDOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-蒽羧酸,7-氟-9,10-二氢-9,10-二羰基- 在 sodium hydroxide 、 四丁基氯化铵 、 水 作用下， 以 氯苯 为溶剂， 反应 6.0h， 以98%的产率得到9,10-Dihydro-9,10-dioxo-7-hydroxyanthracene-2-carboxylic acid
  参考文献：
  名称：

  Anthraquinones related to rhein inhibit glucose uptake into chondrocytes. A mechanism for anti-osteoarthritis drugs?

  摘要：

  Rhein has been shown to inhibit the uptake of glucose into Ehrlich Ascites tumor cells. In this paper we show that a wide range of anthraquinones related to rhein can also inhibit glucose uptake into chondrocytes, many significantly more than the parent molecule. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00102-9

文献信息

• Pharmaceutically active compounds
  申请人：Allen & Hanburys Limited

  公开号：US03984429A1

  公开（公告）日：1976-10-05

  Compounds of the general formula: ##SPC1## Wherein X represents a 5-[1H]-tetrazolyl group, R.sub.1 represents a hydrogen atom, a halogen atom, a hydroxyl group or a group --OR.sub.2, (in which R.sub.2 may be a lower alkyl or alkenyl group containing from 1 to 6 carbon atoms optionally substituted by one or more hydroxy groups, an aryl group, an aryloxy group, an alkoxy group or a dialkylamino group) or a group --NR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which may be the same or different, represent a hydrogen atom, a lower alkyl group containing from 1 to 6 carbon atoms, optionally substituted by a hydroxy group, or R.sub.3 and R.sub.4 together with the nitrogen atom may form a ring which may optionally be substituted with another heteroatom and pharmaceutically acceptable salts thereof. These compounds have useful immunological activity and inhibit the release of spasmogen mediators.

  通式为：##SPC1## 其中X代表一个5-[1H]-四唑基团，R.sub.1代表氢原子、卤原子、羟基或基团--OR.sub.2，(其中R.sub.2可以是含有1至6个碳原子的较低烷基或烯基基团，可选地被一个或多个羟基取代，芳基、芳氧基、烷氧基或二烷基氨基基团)或基团--NR.sub.3 R.sub.4，其中R.sub.3和R.sub.4可以相同也可以不同，代表氢原子、含有1至6个碳原子的较低烷基基团，可选地被羟基取代，或R.sub.3和R.sub.4与氮原子一起可以形成一个环，该环可以可选地被另一个杂原子取代，以及其药用盐。这些化合物具有有用的免疫活性，并抑制痉挛原介质的释放。
• Pharmaceutical compounds
  申请人：Eli Lilly and Company

  公开号：US05430067A1

  公开（公告）日：1995-07-04

  Pharmaceutical compounds as follows: 9,10-dihydro-9,10-dioxo-4,5,8-trimethoxyanthracene-2-carboxylic acid, 4,5-diethoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid, 9,10-dihydro-9,10-dioxo-4,5-dipropoxyanthracene-2-carboxylic acid, 4,5-dibutoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid, 9,10-dihydro-5,8-dimethoxy-9,10-dioxoanthracene-2-carboxylic acid, 7-acetoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid; and salts and esters thereof.

  以下是药物化合物的中文翻译：9,10-二氢-9,10-二氧-4,5,8-三甲氧基蒽-2-羧酸，4,5-二乙氧基-9,10-二氢-9,10-二氧基蒽-2-羧酸，9,10-二氢-9,10-二氧-4,5-二丙氧基蒽-2-羧酸，4,5-二丁氧基-9,10-二氢-9,10-二氧基蒽-2-羧酸，9,10-二氢-5,8-二甲氧基-9,10-二氧基蒽-2-羧酸，7-乙酰氧基-9,10-二氢-9,10-二氧基蒽-2-羧酸；及其盐和酯。
• Tetrazolyl anthraquinones for inhibiting the release of spasmogen
  申请人：Allen & Hanburys Limited

  公开号：US03984534A1

  公开（公告）日：1976-10-05

  Compounds of the general formula: ##SPC1## Wherein X represents a 5-[1H]-tetrazolyl group, R.sub.1 represents a hydrogen atom, a halogen atom, a hydroxyl group or a group --OR.sub.2, (in which R.sub.2 may be a lower alkyl or alkenyl group containing from 1 to 6 carbon atoms optionally substituted by one or more hydroxy groups, an aryl group, an aryloxy group, an alkoxy group or a dialkylamino group) or a group --NR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which may be the same or different, represent a hydrogen atom, a lower alkyl group containing from 1 to 6 carbon atoms, optionally substituted by a hydroxy group, or R.sub.3 and R.sub.4 together with the nitrogen atom may form a ring which may optionally be substituted with another heteroatom and pharmaceutically acceptable salts thereof. These compounds have useful immunological activity and inhibit the release of spasmogen mediators.

  通式为：##SPC1## 的化合物，其中X代表5-[1H]-四唑基团，R.sub.1代表氢原子、卤素原子、羟基或--OR.sub.2基团（其中R.sub.2可以是含有1至6个碳原子的较低烷基或烯基基团，可选地被一个或多个羟基取代，芳基，芳氧基，烷氧基或二烷基氨基基团），或--NR.sub.3 R.sub.4基团，其中R.sub.3和R.sub.4可以相同或不同，代表氢原子，含有1至6个碳原子的较低烷基基团，可选地被羟基取代，或R.sub.3和R.sub.4与氮原子一起形成一个环，该环可以选择性地被另一个杂原子取代，以及其药学上可接受的盐。这些化合物具有有用的免疫活性并抑制痉挛介质的释放。
• Pharmaceutical anthracene-2-carboxylic acid derivatives
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0638540A1

  公开（公告）日：1995-02-15

  Pharmaceutical compounds as follows: 9,10-dihydro-9,10-dioxo-4,5,8-trimethoxyanthracene-2-carboxylic acid, 4,5-diethoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid, 9,10-dihydro-9,10-dioxo-4,5-dipropoxyanthracene-2-carboxylic acid, 4,5-dibutoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid, 9,10-dihydro-5,8-dimethoxy-9,10-dioxoanthracene-2-carboxylic acid, 7-acetoxy-9,10-dihydro-9,10-dioxoanthracene-2-carboxylic acid; and salts and esters thereof.

  药用化合物如下 9,10-二氢-9,10-二氧代-4,5,8-三甲氧基蒽-2-羧酸、 4,5-二乙氧基-9,10-二氢-9,10-二氧代蒽-2-羧酸、 9,10-二氢-9,10-二氧代-4,5-二丙氧基蒽-2-羧酸、 4,5-二丁氧基-9,10-二氢-9,10-二氧代蒽-2-羧酸 9,10-二氢-5,8-二甲氧基-9,10-二氧代蒽-2-羧酸、 7-乙酰氧基-9,10-二氢-9,10-二氧代蒽-2-羧酸； 及其盐类和酯类。
• US5430067A
  申请人：——

  公开号：US5430067A

  公开（公告）日：1995-07-04